DBV Technologies Secures €166.7 Million to Fund Potential US Launch of Peanut Allergy Patch

Châtillon, Saturday, 17 January 2026.
Capitalizing on positive Phase 3 data, DBV Technologies has secured €166.7 million to finance the potential US commercial launch of its VIASKIN peanut allergy patch, effectively extending its operational runway through the critical commercialization phase.